NRX Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 14, 2024 and accepted by EDGAR at Aug 14, 2024, 16:39 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 6 months2024-01-01 to 2024-06-30 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $2.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $4.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$7.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$13.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $0 | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $230.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 6 months2024-01-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$7.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$14.4m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$0.75 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$1.49 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$6.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $0 | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2024-06-30 | $1.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $4.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $5.3m | us-gaap:Assets |
| Total liabilities | At period end2024-06-30 | $23.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | −$18.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-24-026847. Last ingested by Listed: Nov 5, 2026, 19:01 ET. Listed shows no prices and gives no investment advice.